1y4l
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1y4l.gif|left|200px]] | [[Image:1y4l.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1y4l", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | | | + | --> |
| - | | | + | {{STRUCTURE_1y4l| PDB=1y4l | SCENE= }} |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin''' | '''Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin''' | ||
| Line 24: | Line 21: | ||
Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin., Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Elias S, Tomaz MA, Lomonte B, Gutierrez JM, Arni RK, J Mol Biol. 2005 Jul 15;350(3):416-26. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15961104 15961104] | Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin., Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Elias S, Tomaz MA, Lomonte B, Gutierrez JM, Arni RK, J Mol Biol. 2005 Jul 15;350(3):416-26. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15961104 15961104] | ||
[[Category: Bothrops asper]] | [[Category: Bothrops asper]] | ||
| - | [[Category: Phospholipase A(2)]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Arni, R K.]] | [[Category: Arni, R K.]] | ||
| Line 35: | Line 31: | ||
[[Category: Murakami, M T.]] | [[Category: Murakami, M T.]] | ||
[[Category: Tomaz, M A.]] | [[Category: Tomaz, M A.]] | ||
| - | [[Category: | + | [[Category: Anti-trypanosomal drug suramin]] |
| - | [[Category: | + | [[Category: Bothrops asper myotoxin ii]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 15:52:13 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 12:52, 3 May 2008
Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin
Overview
Suramin, a synthetic polysulfonated compound, developed initially for the treatment of African trypanosomiasis and onchocerciasis, is currently used for the treatment of several medically relevant disorders. Suramin, heparin, and other polyanions inhibit the myotoxic activity of Lys49 phospholipase A2 analogues both in vitro and in vivo, and are thus of potential importance as therapeutic agents in the treatment of viperid snake bites. Due to its conformational flexibility around the single bonds that link the central phenyl rings to the secondary amide backbone, the symmetrical suramin molecule binds by an induced-fit mechanism complementing the hydrophobic surfaces of the dimer and adopts a novel conformation that lacks C2 symmetry in the dimeric crystal structure of the suramin-Bothrops asper myotoxin II complex. The simultaneous binding of suramin at the surfaces of the two monomers partially restricts access to the nominal active sites and significantly changes the overall charge of the interfacial recognition face of the protein, resulting in the inhibition of myotoxicity.
About this Structure
1Y4L is a Single protein structure of sequence from Bothrops asper. Full crystallographic information is available from OCA.
Reference
Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin., Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Elias S, Tomaz MA, Lomonte B, Gutierrez JM, Arni RK, J Mol Biol. 2005 Jul 15;350(3):416-26. PMID:15961104 Page seeded by OCA on Sat May 3 15:52:13 2008
